Added to YB: 2024-02-14
Pitch date: 2024-02-12
VNDA [bullish]
Vanda Pharmaceuticals Inc.
+45.58%
current return
Author Info
No bio for this author
Company Info
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
Market Cap
$366.5M
Pitch Price
$4.19
Price Target
9.38 (+54%)
Dividend
N/A
EV/EBITDA
-0.82
P/E
-1.66
EV/Sales
0.53
Sector
Biotechnology
Category
value
Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash
VNDA trades <cash at $4.15 w/ $388M cash & 57.5M shares out. Risks: $100M spent on divested product Janssen litigation generic competition potential FDA rejections. 2 products 1 acquisition 3 possible 2024 FDA approvals. Analysis: $1.65-$13.97/share. Simulation: 20% downside risk. 2024 FDA key for upside. CEO has high ownership.
Read full article (7 min)